Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
02/09/2020
TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
19/08/2020
NG101: Early and locally advanced breast cancer: diagnosis and management
19/08/2020
TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
19/08/2020
TA116: Gemcitabine for the treatment of metastatic breast cancer
19/08/2020
TA124: Pemetrexed for the treatment of non-small-cell lung cancer
18/08/2020
TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
18/08/2020
TA134: Infliximab for the treatment of adults with psoriasis
18/08/2020
TA153: Entecavir for the treatment of chronic hepatitis B
18/08/2020
TA278: Omalizumab for treating severe persistent allergic asthma (replaced TA133)
18/08/2020
TA235: Mifamurtide for the treatment of osteosarcoma
18/08/2020
TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
18/08/2020
TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
18/08/2020
TA191: Capecitabine for the treatment of advanced gastric cancer
18/08/2020
TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)
18/08/2020
TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
18/08/2020
TA247: Tocilizumab for the treatment of rheumatoid arthritis (this has been partially replaced by TA375 - only covers DMARDs, not TNF inhibitors)
18/08/2020
TA177: Alitretinoin for the treatment of severe chronic hand eczema
13/08/2020
TA220: Golimumab for the treatment of psoriatic arthritis
13/08/2020
TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (replaced TA42)
13/08/2020
NG131: Prostate cancer: diagnosis and management
1
2
3
4
5
6
7
8
9
10
11
Follow AWTTC: